Form 4: Vor Biopharma CEO Ang Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Vor Biopharma CEO Robert Ang sold 12,657 shares of common stock on September 3, 2024, to cover tax obligations related to the settlement of restricted stock units.
Summary
- On September 3, 2024, Robert Ang, the President and CEO of Vor Biopharma Inc., disposed of 12,657 shares of common stock.
- The transaction was executed to satisfy tax withholding obligations related to the settlement of restricted stock units.
- The shares were sold at a price of $0.83 per share.
- Following the transaction, Ang directly owns 792,599 shares of Vor Biopharma Inc.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to an insider stock sale for tax purposes, which is a neutral event.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.
Stakeholder Impact
- The sale of shares by the CEO could be perceived negatively by some shareholders, although it is a common practice to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 09/03/2024 | Date of transaction: Robert Ang sold 12,657 shares of Vor Biopharma Inc. |
| 09/04/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.